Program Director's Choice from SABCS2025 - Part 3: Adding Tucatinib to First-line Maintenance Therapy Delayed Disease Progression in HER2-positive Metastatic Breast Cancer in HER2CLIMB-05 Trial

Kate Lathrop, MD discuss one of the high impact, clinically relevant, clinical trial, the HER2CLIMB-05 trail that were presented at the San Antonio Breast Cancer Symposium 2025.

Video: https://medicaldigest.org/scientific-contents/interview:program-directors-choice-sabcs2025-part-3-adding-tucatinib-first-line-maintenance-therapy-delayed-disease-progression-her2-positive-metastatic-breast-cancer-her2climb-05-trial